个体化剂量学在诊疗一体化中的应用:必要、可有可无还是适得其反?
本文综述了诊疗一体化中几种放射性核素组合的剂量学与剂量-效应关系数据,重点讨论分化型甲状腺癌放射性碘治疗和肽受体放射性核素治疗。数据显示健康组织与肿瘤的剂量-效应关系已被证实,且首个治疗周期后的治疗后剂量学可预测后续周期的吸收剂量。作者指出仍需在纳入剂量学概念的临床试验中回答未解问题。
要点
- 123I/124I/131I、68Ga/177Lu、111In/86Y/90Y是诊疗一体化中应用最成功的放射性核素组合。
- 分化型甲状腺癌放射性碘治疗和肽受体放射性核素治疗已证实健康组织与肿瘤的剂量-效应关系。
- 首个治疗周期后的治疗后剂量学可预测后续周期的吸收剂量。
核心结论
- 剂量学概念在分子放疗中具有适用性,但确定治疗活度量的剂量学相关概念仍需在临床试验中回答未解问题。
研究设计与样本
- 本文为综述,汇总多种诊疗一体化化合物的剂量学与剂量-效应关系数据,重点为分化型甲状腺癌放射性碘治疗和肽受体放射性核素治疗。
主要发现
- 123I/124I/131I、68Ga/177Lu和111In/86Y/90Y是目前诊疗一体化中应用最成功的放射性核素组合。
- 分化型甲状腺癌放射性碘治疗和肽受体放射性核素治疗已证实健康组织与肿瘤的剂量-效应关系。
- 首个治疗周期后的治疗后剂量学可预测后续治疗周期的吸收剂量。
局限性
- 原文指出仍需在纳入剂量学概念的临床试验中回答确定治疗活度量的未解问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2005, the term theragnostics (theranostics) was introduced for describing the use of imaging for therapy planning in radiation oncology. In nuclear medicine, this expression describes the use of tracers for predicting the absorbed doses in molecular radiotherapy and, thus, the safety and efficacy of a treatment. At present, the most successful groups of isotopes for this purpose are 123I/124I/131I, 68Ga/177Lu, and 111In/86Y/90Y. The purpose of this review is to summarize available data on the dosimetry and dose-response relationships of several theranostic compounds, with a special focus on radioiodine therapy for differentiated thyroid cancer and peptide receptor radionuclide therapy. These are treatment modalities for which dose-response relationships for healthy tissues and tumors have been demonstrated. In addition, available data demonstrate that posttherapeutic dosimetry after a first treatment cycle predicts the absorbed doses in further cycles. Both examples show the applicability of the concept of theranostics in molecular radiotherapies. Nevertheless, unanswered questions need to be addressed in clinical trials incorporating dosimetry-related concepts for determining the amount of therapeutic activity to be administered.
引用
- Eberlein U, Cremonesi M, Lassmann M, et al. Individualized Dosimetry for Theranostics: Necessary, Nice to Have, or Counterproductive? J Nucl Med. 2017. PMID: 28864620. doi:10.2967/jnumed.116.186841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。